US generics manufacturers renew calls for labelling revisions

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

US generics manufacturers renew calls for labelling revisions

INICIO/Políticas y legislación | Posted 22/05/2015 0 Post your comment

The Generic Pharmaceutical Association (GPhA) has stepped up pressure on the US Food and Drug Administration (FDA) to update its proposed generics labelling requirements. According to GPhA, FDA should adopt the joint alternative proposal known as the Expedited Agency Review (EAR) put forward with the Pharmaceutical Research and Manufacturers of America (PhRMA).

In November 2013, FDA issued a proposed rule that would speed the dissemination of new safety information about generics to health professionals and patients by allowing generics makers to use the same process as brand-name drug manufacturers to update safety information in the product labelling [1].

‘GPhA shares the FDA goals to promote and protect public health,’ said Mr Ralph Neas, President and CEO of GPhA. ‘However, the proposed rule creates a scenario where disparate and potentially conflicting information from multiple manufacturers for single medicines could be widespread, causing confusion and putting patient safety, access and savings at risk.’

GPhA and PhRMA and their supporters call for an alternative to the proposed rule which they say can achieve all of FDA’s objectives related to efficient communication of important safety information [2]. In a letter to FDA, supply chain participants, minority health groups and others wrote ‘We fully support the science-based alternative called the Expedited Agency Review (EAR), which has the support of both generic[s] and brand-name drug manufacturers because it relies on the FDA to review new safety information for multi-source products and requires FDA to take action on a label change made on all multi-source products within a defined time period.’

EAR would establish defined time parameters for FDA to take action on a label change made either following FDA’s receipt and review of ‘new safety information’ from a multi-source application holder or following review of data received through the Sentinel System and/or other databases including global sources that are suggestive of a need for a label change [3].

Related articles
Physicians’ views on biosimilars labelling

FDA re-opens comment period on generics labelling rule

References
1.   GaBI Online - Generics and Biosimilars Initiative. FDA to allow generics makers to change labelling [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 22]. Available from: www.gabionline.net/Policies-Legislation/FDA-to-allow-generics-makers-to-change-labelling
2.   GaBI Online - Generics and Biosimilars Initiative. Alternative proposal for generics labelling [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 22]. Available from: www.gabionline.net/Policies-Legislation/Alternative-proposal-for-generics-labelling
3.   GaBI Online - Generics and Biosimilars Initiative. Drug manufacturers call for revision to FDA safety labelling rule [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 22]. Available from: www.gabionline.net/Policies-Legislation/Drug-manufacturers-call-for-revision-to-FDA-safety-labelling-rule

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: GPhA